AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 01/04/23

Amneal Pharmaceuticals ( NYSE: AMRX ) has signed a long-term license agreement with Orion Corporation to commercialize a number of complex generic products. Under the partnership agreement, Orion is Amneal’s exclusive partner to bring its portfolio of complex generic progra...

- Long-term collaboration to bring Amneal generic products to market in Europe, Australia, and New Zealand Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has signed a long-term license agreement with Orion Corporati...

- 8 new product launches in Q4 closes out another successful year of innovation - First approval of a large volume bag product signals further expansion of injectables business Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences: Piper Sandler 34 th Annual Healthcare Conference December 1, 2022 New York, New York 41 st Annual J....

Second of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO ® (filgrastim-ayow), a biosimilar referenci...

The US FDA has accepted Amneal Pharmaceuticals' ( NYSE: AMRX ) NDA for IPX203 (carbidopa/levodopa) for Parkinson's disease. The agency has provided an action date of June 30, 2023. IPX203 is novel, oral formulation of extended-release carbidopa/levodopa. Phase ...

- IPX203 could offer people living with Parkinson’s disease a longer duration of symptom control with less frequent dosing compared to IR CD/LD treatment - The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 30, 2023. Amneal Pharmaceuticals, Inc...

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2022 Earnings Conference Call November 04, 2022, 08:30 AM ET Company Participants Chirag Patel - Co-Founder, Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Anastasios Konidaris - Executiv...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q3 Non-GAAP EPS of $0.14 misses by $0.04 . Revenue of $545.56M (+3.2% Y/Y) misses by $16.61M . Reaffirms FY2022 Guidance : Reaffirms Net revenue to $2.15B-$2.25B vs. consensus of $2.20B; Adj EPS from pr...